Cite

HARVARD Citation

    Cruickshank, G. et al. (n.d.). Local Delivery Of Irinotecan To Recurrent Glioblastoma At Reoperation Offers A Safe Therapeutic Advantage Over Systemic Delivery. Neuro-oncology. p. i1. [Online]. 
  
Back to record